All In Biotech

Drug Trial Radar · NCT05607550

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 398 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

398

Actual

Start

Jun 1, 2023

Primary completion

Oct 6, 2026

Study completion Feb 15, 2028

Sponsor

Lead sponsor
ArriVent BioPharma, Inc.Industry
Sponsor type
Industry
Collaborators
Allist Pharmaceuticals, Inc.
First posted
Nov 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily \[QD\] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations. A target of approximately 375 patients will be randomized in a 1:1:1 ratio to treatment with furmonertinib 240 mg QD, furmonertinib 160 mg QD, or platinum-based chemotherapy.

Conditions

  • Metastatic Non-Small Cell Lung Cancer
  • Advanced Non-Small Cell Lung Cancer
  • EGFR Exon 20 Mutations

Interventions

  • furmonertinib 240 mg oral, dailyDrug

    furmonertinib tablet

  • furmonertinib 160 mg oral, dailyDrug

    furmonertinib tablet

  • platinum-based chemotherapyDrug

    (carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) determined by blinded independent central review (BICR)Time frame: Up to 32 months after first dose

Locations

208 sites in 19 countries. Site status is shown where the registry gives one.

  • Arrivent Investigative Site

    Daphne, Alabama

  • Arrivent Investigative Site

    Yuma, Arizona

  • Arrivent Investigative Site

    Fayetteville, Arkansas

  • Arrivent Investigative Site

    Beverly Hills, California

  • Arrivent Investigative Site

    Fullerton, California

  • Arrivent Investigative Site

    Long Beach, California

  • Arrivent Investigative Site

    Los Alamitos, California

  • Arrivent Investigative Site

    Napa, California

  • Arrivent Investigative Site

    Orange, California

  • Arrivent Investigative Site

    Orange, California

  • Arrivent Investigative site

    Sacramento, California

  • Arrivent Investigative Site

    San Diego, California

  • Arrivent Investigative Site

    Santa Barbara, California

  • Arrivent Investigative Site

    Santa Monica, California

  • Arrivent Investigative Site

    Santa Rosa, California

  • Arrivent Investigative Site

    Whittier, California

  • Arrivent Investigative Site

    Hartford, Connecticut

  • Arrivent Investigative Site

    Norwich, Connecticut

  • Arrivent Investigative Site

    Fort Myers, Florida

  • Arrivent Investigative Site

    St. Petersburg, Florida

  • Arrivent Investigative Site

    The Villages, Florida

  • Arrivent Investigative Site

    Peoria, Illinois

  • Arrivent Investigative Site

    Rolling Meadows, Illinois

  • Arrivent Investigative Site

    Fort Wayne, Indiana

  • Arrivent Investigative Site

    Indianapolis, Indiana

  • Arrivent Investigative Site

    South Bend, Indiana

  • Arrivent Investigative Site

    Bethesda, Maryland

  • Arrivent Investigative Site

    Frederick, Maryland

  • Arrivent Investigative Site

    Rockville, Maryland

  • Arrivent Investigative Site

    Fairhaven, Massachusetts

  • Arrivent Investigative Site

    Lansing, Michigan

  • Arrivent Investigative Site

    Bolivar, Missouri

  • Arrivent Investigative Site

    Kansas City, Missouri

  • Arrivent Investigative Site

    Saint Joseph, Missouri

  • Arrivent Investigative Site

    St Louis, Missouri

  • Arrivent Investigative Site

    Omaha, Nebraska

  • Arrivent Investigative Site

    Belleville, New Jersey

  • Arrivent Investigative Site

    Englewood, New Jersey

  • Arrivent Investigative Site

    Florham Park, New Jersey

  • Arrivent Investigative Site

    The Bronx, New York

Showing 40 of 208 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.